Protagonist Therapeutics to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera (PV) at ASCO 2022PRNewsWire • 05/26/22
A new generation of ulcerative colitis drugs is in development. Will they be the blockbusters that pharma wants?Market Watch • 05/26/22
ROSEN, A TOP RANKED FIRM, Encourages Protagonist Therapeutics, Inc. Investors With Losses to Inquire About Securities Class Action Investigation - PTGXNewsfile Corp • 05/17/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protagonist Therapeutics, Inc. - PTGXPRNewsWire • 05/11/22
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/05/22
Protagonist Reports First Quarter 2022 Financial Results and Provides Corporate UpdatePRNewsWire • 05/04/22
Investigation Alert: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 04/29/22
Ongoing Investigation Reminder: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 04/28/22
Ongoing Investigation Alert: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 04/27/22
Investigation Reminder: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 04/26/22
Protagonist Therapeutics shares slid after sharing Phase 2 data for its experimental ulcerative colitis treatmentMarket Watch • 04/26/22
Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative ColitisPRNewsWire • 04/25/22
Ongoing Investigation Notice: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 04/25/22
TOP RANKED ROSEN LAW FIRM Encourages Protagonist Therapeutics, Inc. Investors with Losses to Inquire About Securities Class Action Investigation - PTGXPRNewsWire • 04/25/22
EQUITY ALERT: Rosen Law Firm Encourages Protagonist Therapeutics, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – PTGXBusiness Wire • 04/20/22
FDA Intends To Revoke Protagonist Therapeutics' Rusfertide Breakthrough Tag In Rare Form Of Blood CancerBenzinga • 04/14/22
Alpha Cognition Announces Change of CFO, Grant of Stock Options and Addition to the Board of DirectorsBusiness Wire • 04/12/22
Protagonist Therapeutics Announces Appointment of Asif Ali as Executive Vice President and Chief Financial OfficerPRNewsWire • 03/28/22
Protagonist Therapeutics Earns $25 Million Milestone Payment from Janssen Biotech for Dosing of Third Patient in Phase 2b Clinical Trial of PN-235 in Moderate-to-Severe Plaque PsoriasisPRNewsWire • 03/16/22
Protagonist Therapeutics (PTGX) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/01/22
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate UpdatePRNewsWire • 02/28/22